In a randomized trial, an AI alert more than halved the time to an autoimmune diagnosis
Vanderbilt and Johns Hopkins researchers built the open-source AURA tool into health records. In a two-year randomized trial of about 1,960 patients, those with the alert were diagnosed in a median 43 days versus 138.
Read the original
The reporting lives at Johns Hopkins Engineering for Professionals (NEJM AI study). Our summary is checked against it, and we link it on every story.
Researchers at Vanderbilt, in Nashville, and at Johns Hopkins built an open-source tool called AURA into electronic health records, Johns Hopkins Engineering for Professionals reported. The study is published in NEJM AI. In a two-year randomized trial of about 1,960 patients, people whose clinicians received the alert were diagnosed in a median of 43 days, compared with 138 days without it.
That is a shorter wait for a diagnosis, more than cut in half on the median. It is not a treatment and not a cure. The alert flags patients who may be at high risk for autoimmune disease so testing can start sooner. The 43 and 138 figures are medians in this trial, not a promise for every patient.
Health & Tech in MarylandNashville, TennesseeMedical researchPublic healthKindnessGood news on November 6
More good news
Other stories in the same neighborhood of kindness.
Health & TechThe FDA granted accelerated approval to Rybrevant Faspro for head and neck cancer
In a 102-patient trial, subcutaneous amivantamab, sold as Rybrevant Faspro, produced a 42 percent overall response rate in recurrent or metastatic head and neck cancer after chemo and immunotherapy. Confirmatory studies are required.
Verified · U.S. Food and Drug Administration
Health & TechFDA grants accelerated approval to a plasmid DNA therapy for a rare airway disease
The FDA gave Voceryq accelerated approval for adults with recurrent respiratory papillomatosis. In an open-label trial of 32 adults, 7 of 26 heavily treated patients needed no surgery for a year. Confirmatory trials are still required.
Verified · U.S. Food and Drug Administration
Health & TechThe FDA approved an earlier combination for some metastatic prostate cancers
On October 26 the FDA approved talazoparib plus enzalutamide for men with newly diagnosed metastatic prostate cancer that has HRR gene mutations, after a 599-patient trial cut the risk of radiographic progression or death by 52%.
Verified · Healio